VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 701 filers reported holding VANECK VECTORS ETF TR in Q2 2021. The put-call ratio across all filers is 1.04 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $282,555 | -10.6% | 10,500 | 0.0% | 0.15% | -7.8% |
| Q2 2023 | $316,155 | -87.2% | 10,500 | -89.8% | 0.17% | -89.5% |
| Q3 2022 | $2,472,000 | -21.5% | 102,500 | -10.9% | 1.60% | -14.8% |
| Q2 2022 | $3,149,000 | -19.9% | 115,000 | +12.2% | 1.88% | +8.9% |
| Q1 2022 | $3,931,000 | +6.7% | 102,500 | -10.9% | 1.72% | +15.3% |
| Q4 2021 | $3,683,000 | -28.6% | 115,000 | -34.3% | 1.49% | -34.4% |
| Q3 2021 | $5,157,000 | -18.0% | 175,000 | -5.4% | 2.28% | +2.2% |
| Q2 2021 | $6,286,000 | +51.7% | 185,000 | +45.1% | 2.23% | +23.7% |
| Q1 2021 | $4,144,000 | -4.1% | 127,500 | +6.2% | 1.80% | +1.0% |
| Q4 2020 | $4,322,000 | +0.3% | 120,000 | +9.1% | 1.78% | -19.1% |
| Q3 2020 | $4,308,000 | +74.0% | 110,000 | +63.0% | 2.20% | +58.9% |
| Q2 2020 | $2,476,000 | +19.4% | 67,500 | -25.0% | 1.39% | +2.1% |
| Q1 2020 | $2,074,000 | +183.3% | 90,000 | +260.0% | 1.36% | +192.5% |
| Q4 2019 | $732,000 | – | 25,000 | – | 0.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Harbor Financial Group, LLC | 2,418,400 | $77,461,000 | 26.62% |
| Brevan Howard Capital Management LP | 1,000,000 | $32,030,000 | 23.21% |
| Windmill Hill Asset Management Ltd | 844,600 | $27,053,000 | 19.48% |
| Memorial Sloan Kettering Cancer Center | 738,500 | $23,654,000 | 14.86% |
| New Harbor Financial Group, LLC | 1,286,391 | $41,203,000 | 14.16% |
| Eschler Asset Management LLP | 300,000 | $9,609,000 | 12.30% |
| Hollow Brook Wealth Management LLC | 712,669 | $22,827,000 | 11.71% |
| Grand Central Investment Group | 284,547 | $9,114,000 | 10.90% |
| Baymount Management LP | 500,000 | $16,015,000 | 9.54% |
| Nokomis Capital, L.L.C. | 512,628 | $16,419,000 | 6.93% |